PL2688556T3 - Postaci dawkowania o kontrolowanym uwalnianiu - Google Patents
Postaci dawkowania o kontrolowanym uwalnianiuInfo
- Publication number
- PL2688556T3 PL2688556T3 PL12717468T PL12717468T PL2688556T3 PL 2688556 T3 PL2688556 T3 PL 2688556T3 PL 12717468 T PL12717468 T PL 12717468T PL 12717468 T PL12717468 T PL 12717468T PL 2688556 T3 PL2688556 T3 PL 2688556T3
- Authority
- PL
- Poland
- Prior art keywords
- dosage forms
- controlled release
- pharmaceutical dosage
- release pharmaceutical
- controlled
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467824P | 2011-03-25 | 2011-03-25 | |
| EP20120717468 EP2688556B1 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
| PCT/IB2012/000595 WO2012131463A2 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2688556T3 true PL2688556T3 (pl) | 2015-10-30 |
Family
ID=46018006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12717468T PL2688556T3 (pl) | 2011-03-25 | 2012-03-22 | Postaci dawkowania o kontrolowanym uwalnianiu |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20140056979A1 (OSRAM) |
| EP (1) | EP2688556B1 (OSRAM) |
| JP (1) | JP5964940B2 (OSRAM) |
| KR (1) | KR101619579B1 (OSRAM) |
| CN (1) | CN103547259A (OSRAM) |
| AU (1) | AU2012235878B2 (OSRAM) |
| BR (1) | BR112013024585A8 (OSRAM) |
| CA (1) | CA2831218C (OSRAM) |
| CY (1) | CY1116579T1 (OSRAM) |
| DK (1) | DK2688556T3 (OSRAM) |
| ES (1) | ES2544735T3 (OSRAM) |
| HR (1) | HRP20150835T1 (OSRAM) |
| HU (1) | HUE026981T2 (OSRAM) |
| IL (1) | IL228441B (OSRAM) |
| ME (1) | ME02189B (OSRAM) |
| MX (1) | MX350875B (OSRAM) |
| PH (1) | PH12013501994A1 (OSRAM) |
| PL (1) | PL2688556T3 (OSRAM) |
| PT (1) | PT2688556E (OSRAM) |
| RS (1) | RS54152B1 (OSRAM) |
| SI (1) | SI2688556T1 (OSRAM) |
| SM (1) | SMT201500209B (OSRAM) |
| WO (1) | WO2012131463A2 (OSRAM) |
| ZA (1) | ZA201307862B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020059653A (ko) | 1999-10-29 | 2002-07-13 | 그린 마틴, 브라이언 쥐 테슬리 | 서방성 하이드로코돈 제형 |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| US6733783B2 (en) | 2000-10-30 | 2004-05-11 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| US8808740B2 (en) | 2010-12-22 | 2014-08-19 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| JP6279547B2 (ja) | 2012-04-17 | 2018-02-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
| MX2014015880A (es) | 2012-07-06 | 2015-08-05 | Egalet Ltd | Composiciones farmaceuticas disuasivas de abuso para liberacion controlada. |
| PE20151301A1 (es) | 2013-02-05 | 2015-09-16 | Purdue Pharma Lp | Formulaciones farmaceuticas resistentes a la manipulacion indebida |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| WO2019006404A1 (en) | 2017-06-30 | 2019-01-03 | Purdue Pharma L.P. | METHOD OF TREATMENT AND DOSAGE FORMS |
| US11911510B2 (en) | 2017-08-31 | 2024-02-27 | Purdue Pharma L.P | Pharmaceutical dosage forms |
| EP3727384A4 (en) | 2017-12-20 | 2021-11-03 | Purdue Pharma L.P. | ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950007907B1 (ko) * | 1992-09-01 | 1995-07-21 | 동국제약 주식회사 | 치주질환 치료용 막형 국소약물송달제제 |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| US5634702A (en) | 1995-09-27 | 1997-06-03 | Fistonich; Juraj | Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure |
| ATE340563T1 (de) * | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
| US6733783B2 (en) * | 2000-10-30 | 2004-05-11 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| WO2006002884A1 (de) * | 2004-07-01 | 2006-01-12 | Grünenthal GmbH | Gegen missbrauch gesicherte, orale darreichtungsform |
| US7434308B2 (en) * | 2004-09-02 | 2008-10-14 | International Business Machines Corporation | Cooling of substrate using interposer channels |
| WO2006113568A2 (en) * | 2005-04-19 | 2006-10-26 | Alza Corporation | Controlled delivery dosage form of tramadol and gabapentin |
| RU2008149702A (ru) * | 2006-05-17 | 2010-06-27 | Сандвик Интеллекчуал Проперти Аб (Se) | Верхнеударный инструмент для сверления камня, стержень сверла и соединительный рукав |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US8241993B2 (en) * | 2007-07-13 | 2012-08-14 | Marvell World Trade Ltd. | Method for shallow trench isolation |
| CN102105136B (zh) * | 2008-03-11 | 2014-11-26 | 蒂宝制药公司 | 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型 |
| CN101933907A (zh) * | 2009-06-30 | 2011-01-05 | 北京天衡药物研究院 | 新型骨架缓释片及其制备方法 |
-
2012
- 2012-03-22 HU HUE12717468A patent/HUE026981T2/en unknown
- 2012-03-22 HR HRP20150835TT patent/HRP20150835T1/hr unknown
- 2012-03-22 JP JP2014500486A patent/JP5964940B2/ja active Active
- 2012-03-22 DK DK12717468.8T patent/DK2688556T3/en active
- 2012-03-22 BR BR112013024585A patent/BR112013024585A8/pt not_active Application Discontinuation
- 2012-03-22 CA CA2831218A patent/CA2831218C/en active Active
- 2012-03-22 PH PH1/2013/501994A patent/PH12013501994A1/en unknown
- 2012-03-22 AU AU2012235878A patent/AU2012235878B2/en active Active
- 2012-03-22 CN CN201280020303.9A patent/CN103547259A/zh active Pending
- 2012-03-22 EP EP20120717468 patent/EP2688556B1/en active Active
- 2012-03-22 US US14/004,857 patent/US20140056979A1/en not_active Abandoned
- 2012-03-22 PT PT127174688T patent/PT2688556E/pt unknown
- 2012-03-22 ES ES12717468.8T patent/ES2544735T3/es active Active
- 2012-03-22 RS RS20150515A patent/RS54152B1/sr unknown
- 2012-03-22 ME MEP-2015-116A patent/ME02189B/me unknown
- 2012-03-22 WO PCT/IB2012/000595 patent/WO2012131463A2/en not_active Ceased
- 2012-03-22 SI SI201230275T patent/SI2688556T1/sl unknown
- 2012-03-22 KR KR1020137027839A patent/KR101619579B1/ko active Active
- 2012-03-22 MX MX2013010987A patent/MX350875B/es active IP Right Grant
- 2012-03-22 PL PL12717468T patent/PL2688556T3/pl unknown
-
2013
- 2013-09-15 IL IL228441A patent/IL228441B/en active IP Right Grant
- 2013-10-22 ZA ZA2013/07862A patent/ZA201307862B/en unknown
-
2015
- 2015-08-03 CY CY20151100677T patent/CY1116579T1/el unknown
- 2015-09-09 SM SM201500209T patent/SMT201500209B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS54152B1 (sr) | 2015-12-31 |
| KR20130135973A (ko) | 2013-12-11 |
| BR112013024585A8 (pt) | 2018-01-09 |
| WO2012131463A2 (en) | 2012-10-04 |
| JP2014510094A (ja) | 2014-04-24 |
| DK2688556T3 (en) | 2015-08-03 |
| HRP20150835T1 (hr) | 2015-09-11 |
| EP2688556B1 (en) | 2015-05-06 |
| MX350875B (es) | 2017-09-19 |
| PT2688556E (pt) | 2015-09-11 |
| EP2688556A2 (en) | 2014-01-29 |
| IL228441B (en) | 2019-05-30 |
| KR101619579B1 (ko) | 2016-05-10 |
| US20140056979A1 (en) | 2014-02-27 |
| AU2012235878A1 (en) | 2013-05-02 |
| CA2831218C (en) | 2017-01-17 |
| AU2012235878B2 (en) | 2015-10-15 |
| ZA201307862B (en) | 2014-06-25 |
| CN103547259A (zh) | 2014-01-29 |
| NZ616600A (en) | 2015-07-31 |
| ME02189B (me) | 2016-02-20 |
| WO2012131463A3 (en) | 2012-11-29 |
| IL228441A0 (en) | 2013-12-31 |
| CA2831218A1 (en) | 2012-10-04 |
| SMT201500209B (it) | 2015-10-30 |
| JP5964940B2 (ja) | 2016-08-03 |
| CY1116579T1 (el) | 2017-03-15 |
| PH12013501994A1 (en) | 2013-12-02 |
| SI2688556T1 (sl) | 2015-09-30 |
| MX2013010987A (es) | 2014-10-13 |
| HUE026981T2 (en) | 2016-08-29 |
| ES2544735T3 (es) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201307862B (en) | Controlled release pharmaceutical dosage forms | |
| SI2776416T1 (sl) | Farmacevtske spojine | |
| IL227383A0 (en) | Extended-release oral dosage forms containing tsucitinib | |
| SG10201604667YA (en) | Pharmaceutical preparation | |
| IL232305B (en) | Pharmacy preparations | |
| PT2665471T (pt) | Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg | |
| GB201119799D0 (en) | Pharmaceutical compounds | |
| ZA201403832B (en) | Pharmaceutical compounds | |
| ZA201405797B (en) | Pharmaceutical dosage form | |
| PL2726064T3 (pl) | Doustna postać użytkowa o kontrolowanym uwalnianiu zawierająca oksykodon | |
| GB201118876D0 (en) | Pharmaceutical compounds | |
| GB201105298D0 (en) | Pharmaceutical preparation | |
| SI2768485T1 (sl) | Farmacevtska nanosuspenzija | |
| EP2731610A4 (en) | PHARMACEUTICAL COMBINATION | |
| GB201113163D0 (en) | Pharmaceutical compounds | |
| PL2691119T3 (pl) | Preparat farmaceutyczny | |
| ZA201502354B (en) | Pharmaceutical dosage form | |
| GB201113730D0 (en) | Solid dosage form | |
| GB201119796D0 (en) | Pharmaceutical comopounds | |
| GB201118874D0 (en) | Pharmaceutical compounds | |
| GB201105026D0 (en) | Pharmaceutical compounds | |
| GB201117359D0 (en) | Pharmaceutical compounds | |
| GB201118875D0 (en) | Pharmaceutical compounds | |
| ZA201201424B (en) | Pharmaceutical dosage form | |
| GB201111577D0 (en) | Pharmaceutical formulations |